Bioventix PLC (AIM:BVXP)
London
· Delayed Price · Currency is GBP · Price in GBX 1,830.00
-70.00 (-3.68%)
At close: Dec 5, 2025
Bioventix Revenue
In the fiscal year ending June 30, 2025, Bioventix had annual revenue of 13.12M GBP, down -3.61%. Bioventix had revenue of 6.38M in the half year ending June 30, 2025, a decrease of -7.77%.
Revenue
13.12M
Revenue Growth
-3.61%
P/S Ratio
7.29
Revenue / Employee
1.09M
Employees
12
Market Cap
95.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 13.12M | -490.72K | -3.61% |
| Jun 30, 2024 | 13.61M | 790.36K | 6.17% |
| Jun 30, 2023 | 12.82M | 1.10M | 9.36% |
| Jun 30, 2022 | 11.72M | 788.68K | 7.22% |
| Jun 30, 2021 | 10.93M | 617.01K | 5.98% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Convatec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
Bioventix News
- 5 weeks ago - AIM Market Roundup: Angle, Coyngar, Light Science Technologies - The Armchair Trader